Reuters logo
BRIEF-XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA
February 16, 2017 / 4:40 PM / 9 months ago

BRIEF-XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA

Feb 16 (Reuters) - Xbiotech Inc :

* XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA (HS)

* XBIOTECH INC - STUDY DEMONSTRATED SIGNIFICANT IMPROVEMENT OF HS PATIENTS COMPARED TO CONTROL AFTER 12 WEEKS OF THERAPY Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below